+43-123-13-985|info@ces.b2sg.org
Loading Events
  • This event has passed.

SELECTBIO is thrilled to announce the continuation of Epigenetics in Drug Discovery for 2017.

The event will form part of the multi-track conference, Advances in Drug Discovery, and will run alongside three additional tracks: Antibodies in Drug Discovery, Academic Drug Discovery and Stem Cells in Drug Discovery.

As a multi-track event, delegates will have unrestricted access to all conference tracks and networking opportunities. Attracting researchers from both academia and industry, this track will explore the latest opportunities and challenges for epigeneticists looking to discover and develop new molecular entities. Topics to be addressed include, assays for Methyltranferases and Demethylases, Bromodomain inhibitor discovery, indications beyond cancer, Non-BET Bromodomains and of course updates in Oncology.

Thanks to vast steps forwards in this field, epigenetic compounds are becoming more and more common in both pre-clinical and clinical drug discovery. If you work in epigenetics research, you will benefit from the expert knowledge of academic and industry leaders who are pushing the boundaries of drug discovery, whilst networking with the technology providers who are enabling them to do so.

The Cancer Epigenetics Society is a Supporting organization for this meeting, and our members are eligible for a 20% discount on registration fees. Please contact the Cancer Epigenetics Society at info@ces.b2sg.org to claim the discount.